Actively Recruiting
Study to Evaluate REGN7508 and REGN9933 Versus Placebo for Stroke Prevention in Adults With Atrial Fibrillation Unsuitable for Blood Thinners
Led by Regeneron Pharmaceuticals · Updated on 2026-10-14
2628
Participants Needed
44
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying two experimental drugs, REGN7508 and REGN9933, to prevent blood clots in adults with atrial fibrillation, a condition where the heart beats irregularly and too fast. This study focuses on people who cannot or choose not to take blood thinners, aiming to assess how well these drugs work and their safety in reducing risks of ischemic stroke, systemic embolism, and major cardiovascular problems. Participants will be randomly assigned to receive REGN7508, REGN9933, or a placebo, with treatments given according to the study protocol. The study will monitor the presence of the drugs in the blood, any antibodies the body makes against the drugs, and several health outcomes over up to 36 months. The study is double-blind, meaning participants and researchers do not know who receives which treatment. During the study, participants will have regular evaluations for stroke, systemic embolism, major cardiovascular events, bleeding occurrences, and overall survival. Researchers will also track side effects, blood clotting times, and drug concentration levels. The study includes long-term follow-up for up to 39 months to carefully monitor safety and effectiveness outcomes throughout the participation period.
CONDITIONS
Brief Title
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here